Drugmaker Lupin has entered into a Settlement and License Agreement with Astellas Pharma Inc, involving a patent infringement dispute over its product ‘Mirabegron’.“Lupin will pay Astellas $90 million, which includes a Prepaid Option Payment of $75 million, and a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027,” the company told the stock exchanges.The product is indicated for treating an overactive bladder with symptoms of urge urinary ...